![]() | This article needs more reliable medical references for verification or relies too heavily on primary sources .(March 2021) |
![]() | |
Names | |
---|---|
IUPAC name 4-(Diaminomethylideneamino)butyl 4-hydroxy-3,5-dimethoxybenzoate | |
Identifiers | |
3D model (JSmol) | |
ChemSpider | |
ECHA InfoCard | 100.208.686 |
KEGG | |
PubChem CID | |
UNII | |
CompTox Dashboard (EPA) | |
| |
| |
Properties | |
C14H21N3O5 | |
Molar mass | 311.338 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Leonurine (also known as SCM-198 in research) is a pseudoalkaloid that has been isolated from Leonotis leonurus , Leonotis nepetifolia , Leonurus japonicus , Leonurus cardiaca (motherwort), Leonurus sibiricus , as well as other plants of family Lamiaceae.[ citation needed ] Leonurine is easily extracted into water. [1]
Leonurine weakly binds to multiple GABA receptor sites including the GABAA receptor. [2] [3] However, it shows much higher affinity as a 5-HT3A receptor antagonist. [4] 5-HT3A antagonists have been shown to help prevent nausea and vomiting as well as the negative effects of serotonin in the gastrointestinal tract. [5] [6]
Leonurine can regulate a variety of functions including oxidative stress, inflammation, fibrosis, apoptosis, and metabolic disorder. [7] [8] [9]
Leonurine has demonstrated antidepressant-like action and has been shown to increase levels of serotonin, noradrenaline, and dopamine in chronic mild stress studies on mice and inhibits the production of pro-inflammatory cytokines. [10] [11] [12]
Leonurine has been investigated as a potential treatment for cardiovascular disorders. [13] [14] [15] [16] It protects against oxidative damage from ischemic stroke and demonstrates neuroprotective activity against focal cerebral ischemia brain injury induced on rats. [17] [18] [19]
Leonurine protects mice from pneumonia induced by influenza A. [20]
Leonurine has demonstrated anti-cancer activity in vitro and in animal studies. [21] [22] [23] [24] [25]
Metabolites of leonurine in rats dosed orally include leonurine-10-O-sulfate (the sulfate conjugate of leonurine), leonurine-10-O-β-D-glucuronide (the glucuronide metabolite of leonurine) and an O-demethylated leonurine analog that has not yet had its structure definitively confirmed. [26]
Leonurine can be synthesized starting from eudesmic acid. Reaction with sulfuric acid produces syringic acid. Protection with ethyl chloroformate followed by reaction with thionyl chloride (SOCl2) and then tetrahydrofuran yields 4-carboethoxysyringic acid 4-chloro-1-butyl ester. The chloride is then converted to an amino group via a Gabriel synthesis (with potassium phthalimide) followed by hydrazinolysis (Ing–Manske procedure). The final step is reaction of the amine with S-methylisothiourea hemisulfate salt.